PHAT News and Press, Phathom Pharmaceuticals Inc. From 01/01/24

2024-01-01 06:41:03 ET Summary Phathom Pharmaceuticals' stock is down 35% from its August highs and is now trading at $9. The company has two approved indications for its drug vonoprazan and an upcoming PDUFA. Phathom has a cash balance of $213mn and a cash runway of 8-9 quart...

2023-12-14 10:06:03 ET More on Hercules Capital, Phathom Pharmaceuticals, etc. Main Street Capital Vs. Hercules Capital: Why Choose? Hercules Capital: This 10% Yield Is Solidly Covered By NII (Upgrade) Hercules Capital: 10% Yield, My Largest BDC Position Phat...

Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027 Up to an additional $100 million in non- dilutive capital available subject to the achievement of certain revenue milestones Cash runway...

2023-12-06 08:44:34 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom Pharmaceuticals gets FDA approval for Erosive GERD drug Phathom wins FDA nod for reformulated antibiotic Seeking Alpha’s Quant Rating on Phathom Phar...

New drug application (NDA) seeks U.S. Food and Drug Administration (FDA) approval for VOQUEZNA® as a daily treatment for heartburn associated with Non-Erosive GERD, the largest subcategory of GERD July 19, 2024 PDUFA target action date assigned by the FDA FLORHAM PARK, ...

VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets in 30-count bottles are now commercially available for the healing and ...

Phathom Pharmaceuticals Inc. (PHAT) is expected to report $-0.95 for Q3 2023

2023-11-09 17:15:33 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom Pharmaceuticals gets FDA approval for Erosive GERD drug Phathom wins FDA nod for reformulated antibiotic For further details see: Phantom Pharmaceutical...

2023-11-09 09:07:48 ET More on Phathom Pharmaceuticals Following Up On Phathom Pharmaceuticals Phathom Pharmaceuticals gets FDA approval for Erosive GERD drug Phathom wins FDA nod for reformulated antibiotic Seeking Alpha’s Quant Rating on Phathom Phar...

VOQUEZNA® (vonoprazan) tablets approved by the U.S. Food and Drug Administration (FDA) for the treatment of Erosive GERD and relief of associated heartburn in adults, marking the first major innovation in the U.S. Erosive GERD market in over 30 years Commercial availability of VOQUEZNA f...